menu
Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics to Present Data at the European Society of Gene & Cell Therapy Congress

CAMBRIDGE, Mass. , Oct. 14, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that members of its scientific team will present new data at the
Read More

Intellia Therapeutics to Present at Jefferies Gene Editing/Therapy Summit

CAMBRIDGE, Mass. , Oct. 05, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that Chief Medical Officer John Leonard , M.D., will participate
Read More

Intellia Therapeutics to Present at September Investor Healthcare Conferences

CAMBRIDGE, Mass. , Sept. 01, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that CEO and Founder Nessan Bermingham , Ph.D., will present at
Read More

Intellia Therapeutics’ Preclinical Data Show Continued Progress in In Vivo Gene Editing With Systemic Lipid Nanoparticle Delivery of CRISPR/Cas9 components

CAMBRIDGE, Mass. , Aug. 18, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, presented preclinical data demonstrating in vivo gene editing using lipid
Read More

Intellia Therapeutics to Present at 2016 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass. , Aug. 10, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that CEO and Founder Nessan Bermingham , Ph.D., will present at
Read More

Intellia Therapeutics Reports Financial Results for Second Quarter 2016

Advancing proprietary and partnered pipeline candidates with Novartis and Regeneron Cash and cash equivalents of approximately $300.7 million to accelerate CRISPR/Cas9 platform and pipeline development  CAMBRIDGE, Mass. , Aug. 04, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.
Read More

Intellia Therapeutics to Present at the Jefferies 2016 Healthcare Conference and the International BIO Convention

CAMBRIDGE, Mass. , June 03, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading gene editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, will present at both the upcoming Jefferies 2016 Healthcare Conference and the
Read More

Intellia Therapeutics Announces Closing of Initial Public Offering

Underwriters Exercise Over-Allotment Option CAMBRIDGE, Mass. , May 11, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) today announced the closing of its initial public offering of 6,900,000 shares of its common stock at an initial public offering price of $18.00 per share, which
Read More

Intellia Therapeutics Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass. , May 05, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (”Intellia Therapeutics” or “Intellia”) a leading gene editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today announced the pricing of its initial public
Read More

Intellia Therapeutics Appoints Perry Karsen as Chairman of its Board of Directors

CAMBRIDGE, MASS. – April 22, 2016 — Intellia Therapeutics, Inc., a leading gene-editing company, has named Perry Karsen as the Chairman of its Board of Directors. Mr. Karsen held leadership positions at Celgene Corporation, including Chief Operations Officer and Executive Vice President and
Read More
RSS FEEDS
PRINT PAGE